Halozyme and Incyte Team Up to Explore Easier Subcutaneous Delivery for INCA033989

Global Collaboration Will Evaluate Halozyme’s Enhanze Technology

Halozyme Therapeutics and Incyte have entered into a global collaboration and license agreement to explore new subcutaneous formulations of INCA033989, an investigational monoclonal antibody being developed for patients with mutant calreticulin, or mutCALR, expressing myeloproliferative neoplasms (MPNs).

The collaboration will use Halozyme’s proprietary Enhanze drug delivery technology. The goal is to see whether the technology can improve the subcutaneous formulation of INCA033989 that is already in development.

For patients, the focus is simple: making treatment easier and more convenient to receive.

What Is INCA033989?

INCA033989 is described as a first-in-class monoclonal antibody that targets mutant calreticulin, also known as mutCALR.

The drug is being developed for patients with mutCALR-expressing myeloproliferative neoplasms. MPNs are a group of blood cancers in which the bone marrow produces abnormal numbers of blood cells.

INCA033989 is still under development, so its safety and effectiveness are still being evaluated in clinical development.

The collaboration between Halozyme and Incyte is focused on exploring additional ways to deliver the medicine through a subcutaneous formulation.

Why Subcutaneous Delivery Matters

Many medicines are given through intravenous infusions or other methods that can require more time and resources for patients and healthcare providers.

Subcutaneous delivery means a medicine can be administered under the skin. Depending on the medicine and its formulation, this approach may make treatment more convenient and potentially reduce the burden associated with administration.

That is where Halozyme's Enhanze technology comes into the picture.

The companies will evaluate whether Enhanze can strengthen the subcutaneous formulation of INCA033989 and potentially support more convenient delivery and dosing options.

Halozyme Brings Its Enhanze Technology

Enhanze is Halozyme's proprietary drug delivery technology. It uses the enzyme rHuPH20 to help facilitate the subcutaneous delivery of injected medicines and fluids.

The technology is designed to help medicines that may otherwise need to be delivered through more time-consuming administration methods.

Halozyme has worked with multiple biopharmaceutical companies to apply Enhanze across different therapeutic areas. The company says the technology is intended to reduce treatment burden and improve convenience for patients.

In this collaboration, the technology will be explored specifically in connection with INCA033989.

What the Collaboration Will Focus On

The main goal of the collaboration is to evaluate additional subcutaneous formulations of INCA033989.

The companies will look at whether Enhanze can improve the formulation currently being developed by Incyte. If successful, the approach could potentially support more convenient treatment delivery for people with mutCALR-expressing MPNs.

The collaboration may also expand beyond the initial programme. Under the agreement, Incyte has the option to nominate up to two additional targets for use with Enhanze.

This gives the partnership the potential to explore the drug delivery technology with additional programmes in the future.

Financial Terms of the Agreement

Under the terms of the global collaboration and license agreement, Halozyme will receive an upfront payment from Incyte.

Halozyme is also eligible to receive additional payments if agreed development milestones are achieved.

The company may also receive royalties on net sales of commercialized medicines that use Enhanze technology.

The financial details of the upfront payment and potential milestone payments were not disclosed in the announcement.

What Halozyme Says About the Deal

Dr. Helen Torley, president and chief executive officer of Halozyme, said the collaboration reflects the continued interest in the company's Enhanze technology across important areas of medicine.

She also highlighted Incyte's experience in hematology and said the companies will work together to explore more convenient subcutaneous treatment options.

For Halozyme, the agreement also adds another partnered programme to its broader portfolio of collaborations with biopharmaceutical companies.

A Focus on Improving the Treatment Experience

For patients living with serious diseases, the treatment itself is only one part of the experience. How often a medicine is given and how it is administered can also affect daily life.

This is particularly relevant for therapies that may require repeated or long-term treatment.

By exploring a subcutaneous formulation of INCA033989 with Enhanze, Halozyme and Incyte are looking at whether the treatment experience can be made more convenient without changing the underlying therapeutic target.

The companies will need to complete development and evaluation work before it is known whether the approach can advance into a commercially available treatment.

Halozyme's Broader Drug Delivery Platform

Halozyme is focused on developing drug delivery solutions that can be used with emerging and established therapies.

Its Enhanze technology is based on the proprietary enzyme rHuPH20 and is designed to facilitate the subcutaneous administration of injected drugs and fluids.

The company has built collaborations with biopharmaceutical companies across multiple therapeutic areas, using the technology to explore ways to reduce treatment burden and improve convenience.

The new agreement with Incyte adds a programme in hematology to this collaboration portfolio, with the initial focus on INCA033989 and the possibility of adding up to two more targets in the future.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!